Live Breaking News & Updates on Aralez Pharmaceuticals|Page 5

Stay updated with breaking news from Aralez pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Titan Medical Expands Senior Leadership Team


Nasdaq:
TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Kristen Galfetti, MBA, as its Vice President, Investor Relations & Corporate Communications and Chien Huang as Vice President Finance. Ms. Galfetti will be located in Boston and Mr. Huang will be located in Toronto.
It is a pleasure to welcome both Kristen and Chien to Titan Medical. As the Titan team continues to grow and advance our Enos™ robotic single access surgery system toward human clinical studies, we look forward to these two accomplished leaders significantly contributing to our success, said David McNally, President and Chief Executive Officer of Titan. Kristen and Chien have each demonstrated a record of success in their respective fields, and we are proud that they have joined our leadership team. ....

United States , Astellas Pharma , David Mcnally , Kristen Galfetti , Titan Medical Inc , Bentley University , Corporate Finance At Quarterhill Inc , Company Annual Information Form , Master Of Business Administration , University Of Toronto , Corporate Communications , Investor Relations Corporate Communications At Cynapsus Therapeutics , Aralez Pharmaceuticals , Mcgill University , University Of Vermont , Investor Relations Corporate Communications , Genzyme Corporation , Vice President , Investor Relations , Chien Huang , Chief Executive Officer , Senior Director , Political Science , Business Administration , Senior Vice President , Corporate Finance ,

Miravo Healthcare™ Ireland Enters into Suvexx® License and Supply Agreement with Orion Corporation for Select EU Markets


- Up to EUR 1.7 million in upfront and milestone payments -  
MISSISSAUGA, ON, Dec. 21, 2020 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (TSX:NRI) (OTCQX:NRIFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare (Miravo Ireland), has entered into an exclusive license and supply agreement (the License Agreement) with Orion Corporation (Orion) for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia (the Territory). ....

United States , Eteläuomen Läi , Nuvo Pharmaceuticals Inc , Orion Corporation , Nuvo Pharmaceuticals Ireland , Currax Holdings United States , Glaxo Group , Pozen Inc , Drug Administration , Aralez Pharmaceuticals Inc , Gsk Rt Technology , Health Canada , European Partnering Deal , Miravo Healthcare , Nuvo Pharmaceuticals , Miravo Ireland , License Agreement , Nasdaq Helsinki , Jesse Ledger , Aralez Pharmaceuticals , Glaxo Group Limited , Good Manufacturing Practices , Annual Information Form , ஒன்றுபட்டது மாநிலங்களில் , நூவோ மருந்துகள் இன்க் , ஒரையந் நிறுவனம் ,